PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)

• Lucia Masarova,
• Srdan Verstovsek,
• Tom Liu,
• Sumati Rao,
• Guatam Sajeev,
• Ryan Simpson,
• Weilong LI,
• Joseph Yang,
• Boris Gorsh,
• James Signorovitch

Affiliations

Lucia Masarova

1 The University of Texas MD Anderson Cancer Center, Houston, United States

Srdan Verstovsek

1 The University of Texas MD Anderson Cancer Center, Houston, United States

Tom Liu

2 GlaxoSmithKline, Collegeville, United States

Sumati Rao

2 GlaxoSmithKline, Collegeville, United States

Guatam Sajeev

3 Analysis Group, Boston, United States

Ryan Simpson

3 Analysis Group, Boston, United States

Weilong LI

3 Analysis Group, Boston, United States

Joseph Yang

2 GlaxoSmithKline, Collegeville, United States

Boris Gorsh

2 GlaxoSmithKline, Collegeville, United States

James Signorovitch

3 Analysis Group, Boston, United States